Lu Wang

26.2k total citations · 3 hit papers
552 papers, 14.1k citations indexed

About

Lu Wang is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Lu Wang has authored 552 papers receiving a total of 14.1k indexed citations (citations by other indexed papers that have themselves been cited), including 193 papers in Molecular Biology, 127 papers in Pulmonary and Respiratory Medicine and 119 papers in Oncology. Recurrent topics in Lu Wang's work include Lung Cancer Treatments and Mutations (34 papers), Cancer Genomics and Diagnostics (33 papers) and Sarcoma Diagnosis and Treatment (33 papers). Lu Wang is often cited by papers focused on Lung Cancer Treatments and Mutations (34 papers), Cancer Genomics and Diagnostics (33 papers) and Sarcoma Diagnosis and Treatment (33 papers). Lu Wang collaborates with scholars based in China, United States and Canada. Lu Wang's co-authors include Marc Ladanyi, Mark G. Kris, Alexander Drilon, Stephen C. Winans, Maureen F. Zakowski, Meera Hameed, Adrienne T. Dennis, Eckhard Ficker, Arthur Brown and Maria E. Arcila and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Lu Wang

520 papers receiving 13.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

High-throughput genotyping by whole-genome resequencing

2009 646 citations Lu Wang et al. profile →
The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma

2011 512 citations Tatsuo Ito, Lu Wang et al. profile →
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial

2016 327 citations Alexander Drilon, Natasha Rekhtman et al. profile →

Peers

Countries citing papers authored by Lu Wang

Since Specialization

Citations

This map shows the geographic impact of Lu Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lu Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lu Wang more than expected).

Fields of papers citing papers by Lu Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lu Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lu Wang. The network helps show where Lu Wang may publish in the future.

Co-authorship network of co-authors of Lu Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Lu Wang. A scholar is included among the top collaborators of Lu Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lu Wang. Lu Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Comprehensive characterization and database construction of immune repertoire in the largest Chinese glioma cohort 2023 ·iScience ·Lu Wang, (unknown), Wei Zhang, Lin Li, Xiao Liu, Jing Zhang	0
2	Structural basis of transcription activation by the global regulator Spx 2021 ·Nucleic Acids Research ·Jing Shi, Fangfang Li, Aijia Wen, Libing Yu, Lu Wang, (unknown), (unknown), Sha Jin, Yu Feng, Wei Lin	20
3	PAX9 Determines Epigenetic State Transition and Cell Fate in Cancer 2021 ·Cancer Research ·Zibo Zhao, (unknown), (unknown), Hiam Abdala‐Valencia, Young Ah Goo, Benjamin D. Singer, Elizabeth T. Bartom, Feng Yue, Lu Wang	15
4	Clinical Genomic Sequencing of Pediatric and Adult Osteosarcoma Reveals Distinct Molecular Subsets with Potentially Targetable Alterations 2019 ·Clinical Cancer Research ·Yoshiyuki Suehara, Deepu Alex, Anita S. Bowman, Sumit Middha, Ahmet Zehir, Debyani Chakravarty, Lu Wang, George Jour, Khédoudja Nafa, Takuo Hayashi, Achim A. Jungbluth, Denise Frosina, Emily K. Slotkin, Neerav Shukla, Paul A. Meyers, John H. Healey, Meera Hameed, Marc Ladanyi	98
5	The Transcription Factor AP4 Promotes Oncogenic Phenotypes and Cisplatin Resistance by Regulating LAPTM4B Expression 2018 ·Molecular Cancer Research ·Lu Wang, Yue Meng, (unknown), Qingyun Zhang	15
6	Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition 2017 ·Cancer Research ·Rona Yaeger, Zhan Yao, David M. Hyman, Jaclyn F. Hechtman, Efsevia Vakiani, HuiYong Zhao, Wenjing Su, Lu Wang, Andrew Joelson, Andrea Cercek, José Baselga, Elisa de Stanchina, Leonard B. Saltz, Michael F. Berger, David B. Solit, Neal Rosen	60
7	Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases 2017 ·Clinical Cancer Research ·Charlotte K.Y. Ng, François‐Clément Bidard, Salvatore Piscuoglio, Felipe C. Geyer, Raymond S. Lim, Ino de Bruijn, Ronglai Shen, Fresia Pareja, Samuel Berman, Lu Wang, Jean‐Yves Pierga, Anne Vincent‐Salomon, Agnès Viale, Larry Norton, Brigitte Sigal, Britta Weigelt, Paul Cottu, Jorge S. Reis‐Filho	83
8	SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer 2017 ·Cancer Research ·Eiki Ichihara, David Westover, Catherine B. Meador, Yingjun Yan, Joshua A. Bauer, Lu Wang, Fei Ye, Amanda Kulick, Elisa de Stanchina, Robert McEwen, Marc Ladanyi, Darren A.E. Cross, William Pao, Christine M. Lovly	104
9	The Ephrin-A1/EPHA2 Signaling Axis Regulates Glutamine Metabolism in HER2-Positive Breast Cancer 2016 ·Cancer Research ·Victoria Youngblood, Laura C. Kim, Deanna N. Edwards, Yoonha Hwang, (unknown), Steven M. Stirdivant, Lu Wang, Fei Ye, Dana M. Brantley‐Sieders, Jin Chen	61
10	Osteosarcoma With Apparent Ewing Sarcoma Gene Rearrangement 2016 ·Journal of Pediatric Hematology/Oncology ·Melissa Mathias, Alexander J. Chou, Paul A. Meyers, Neerav Shukla, Meera Hameed, Narasimhan P. Agaram, Lu Wang, Michael F. Berger, Michael F. Walsh, Alex Kentsis	2
11	EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer 2016 ·Cancer Research ·Katherine Amato, Shan Wang, Li Tan, Andrew K. Hastings, Wenqiang Song, Christine M. Lovly, Catherine B. Meador, Fei Ye, Lu Wang, Justin M. Balko, Daniel C. Colvin, Justin Cates, William Pao, Nathanael S. Gray, Jin Chen	84
12	Comprehensive Molecular Characterization of Salivary Duct Carcinoma Reveals Actionable Targets and Similarity to Apocrine Breast Cancer 2016 ·Clinical Cancer Research ·Martin G. Dalin, Alexis Desrichard, Nora Katabi, Vladimir Makarov, Logan A. Walsh, Ken-Wing Lee, Qingguo Wang, Joshua Armenia, Lyndsay West, Snjezana Doğan, Lu Wang, Deepa Ramaswami, Alan L. Ho, Ian Ganly, David B. Solit, Michael F. Berger, Nikolaus Schultz, Jorge S. Reis‐Filho, Timothy A. Chan, Luc G.T. Morris	135
13	Identification of Targetable Kinase Alterations in Patients with Colorectal Carcinoma That are Preferentially Associated with Wild-Type RAS/RAF 2015 ·Molecular Cancer Research ·Jaclyn F. Hechtman, Ahmet Zehir, Rona Yaeger, Lu Wang, Sumit Middha, Tao Zheng, David M. Hyman, David B. Solit, Maria E. Arcila, Laetitia Borsu, Jinru Shia, Efsevia Vakiani, Leonard B. Saltz, Marc Ladanyi	43
14	Next-Generation Sequencing of Stage IV Squamous Cell Lung Cancers Reveals an Association of PI3K Aberrations and Evidence of Clonal Heterogeneity in Patients with Brain Metastases 2015 ·Cancer Discovery ·Paul K. Paik, Ronglai Shen, Helen Won, Natasha Rekhtman, Lu Wang, Camelia S. Sima, Arshi Arora, Venkatraman Seshan, Marc Ladanyi, Michael F. Berger, Mark G. Kris	111
15	Broad, Hybrid Capture–Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches 2015 ·Clinical Cancer Research ·Alexander Drilon, Lu Wang, Maria E. Arcila, Sohail Balasubramanian, Joel Greenbowe, Jeffrey S. Ross, Phil Stephens, Doron Lipson, Vincent A. Miller, Mark G. Kris, Marc Ladanyi, Naiyer A. Rizvi	202
16	A Novel Crizotinib-Resistant Solvent-Front Mutation Responsive to Cabozantinib Therapy in a Patient with ROS1 -Rearranged Lung Cancer 2015 ·Clinical Cancer Research ·Alexander Drilon, Romel Somwar, Jacob P. Wagner, Nadeem A. Vellore, Christopher A. Eide, Matthew S. Zabriskie, Maria E. Arcila, Jaclyn F. Hechtman, Lu Wang, Roger S. Smith, Mark G. Kris, Gregory J. Riely, Brian Druker, Thomas O’Hare, Marc Ladanyi, Monika A. Davare	128
17	Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer 2014 ·Molecular Cancer Therapeutics ·Catherine B. Meador, Hailing Jin, Elisa de Stanchina, Caroline A. Nebhan, Valentina Pirazzoli, Lu Wang, Huy Gia Vuong, Katherine E. Hutchinson, Peilin Jia, Xi Chen, Rosana Eisenberg, Marc Ladanyi, Katerina Politi, Zhongming Zhao, Christine M. Lovly, Darren A.E. Cross, William Pao	22
18	Smoking Induces Epithelial-to-Mesenchymal Transition in Non–Small Cell Lung Cancer through HDAC-Mediated Downregulation of E-Cadherin 2012 ·Molecular Cancer Therapeutics ·Nagaraj S. Nagathihalli, Pierre P. Massion, Adriana L. Gonzalez, Lu Wang, Pran K. Datta	77
19	Identification of KIF5B-RET and GOPC-ROS1 Fusions in Lung Adenocarcinomas through a Comprehensive mRNA-Based Screen for Tyrosine Kinase Fusions 2012 ·Clinical Cancer Research ·Yoshiyuki Suehara, Maria E. Arcila, Lu Wang, Adnan Hasanovic, Daphne Ang, Tatsuo Ito, (unknown), Alexander Drilon, Udayan Guha, Valerie W. Rusch, Mark G. Kris, Maureen F. Zakowski, Naiyer A. Rizvi, Raya Khanin, Marc Ladanyi	132
20	RAF265 Inhibits the Growth of Advanced Human Melanoma Tumors 2012 ·Clinical Cancer Research ·Yingjun Su, Anna E. Vilgelm, Mark C. Kelley, Oriana E. Hawkins, Yan Liu, Kelli L. Boyd, Sara Kantrow, Ryan Splittgerber, Sarah P. Short, Tammy Sobolik, Snjezana Zaja‐Milatovic, Kimberly B. Dahlman, Katayoun I. Amiri, Aixiang Jiang, Lu Wang, Yu Shyr, Darrin D. Stuart, Shawn Levy, Jeffrey A. Sosman, Ann Richmond	47

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact